Welcome : Guest

Eagle Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Eagle Pharmaceuticals, Inc., which is principally involved in Specialty Pharmaceuticals Business. Illustrated with 72 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-64232
Price: $3500
Company Type: Public
Pages: 74
Date: November 2016
Market Data Tables: 72

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Specialty Pharma & Orphan Drugs......3
Table 1: Specialty Pharma & Orphan Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Europe, US and Rest of the World......3
Cancer Drugs......4
Table 2: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......4
Table 3: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......5
Cancer Market......6
Table 4: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......6
Table 5: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......7
Table 6: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......8
Table 7: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......9
Table 8: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......10
Table 9: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......11
Table 10: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......12
Table 11: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......13
Cancer Patients......14
Table 12: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......14
Table 13: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......15
Table 14: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......16
Table 15: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......17
Table 16: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......18
Table 17: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......19
Table 18: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......20
Table 19: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......21
Table 20: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......22
Table 21: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......23
Table 22: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......24
Table 23: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......25
Table 24: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......26
Table 25: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......27
Table 26: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......28
Table 27: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......29
Table 28: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......30
Table 29: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......31
Table 30: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......32
Table 31: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......33
Table 32: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......34
Cervical Cancer......35
Table 33: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......35
Table 34: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......36
Hematological Cancer......37
Table 35: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......37
Skin Cancer......38
Table 36: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......38
Cancer-Associated Mucositis......39
Table 37: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......39
Chronic Myelogenous Leukemia (CML)......40
Table 38: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......40
Multiple Myeloma......41
Table 39: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......41
Table 40: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......42
Rheumatoid Arthritis......43
Table 41: Rheumatoid Arthritis Market by Product Type Worldwide (2015) - Percentage Share Breakdown by Value Sales for ENBREL, HUMIRA, REMICADE, and Others......43
Anti-Osteoarthritis......44
Table 42: Anti-Osteoarthritis Market in Korea (2015-2020) in KRW Million......44
Percutaneous Coronary Intervention (PCI)......45
Table 43: Vascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Diagnostic (Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)), Percutaneous Coronary Intervention (PCI), Peripheral Interventions, and Structural Vascular......45
Table 44: Coronary Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Percutaneous Coronary Intervention (PCI) Complex Cases, and Single Vessel, Single Stent......46
Low-Molecular-Weight Heparin......47
Table 45: Anticoagulation Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Direct Thrombin Inhibitors (DTI), Low-Molecular-Weight Heparin (LMWH), Unfractionated Heparin (UFH), Vitamin K Antagonists (VKA) and Others......47
Table 46: Anticoagulant Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Heparin, Low-Molecular-Weight Heparin (LMWH), Novel Oral Anticoagulants, Warfarin, and Other Injectable Anticoagulants......48
Table 47: Low-Molecular-Weight Heparin Market by Product in China (2015) - Percentage Share Breakdown by Value for Clexane (Sanofi-Aventis), Fluxum (Alfa Wassermann), Fraxiparine (GSK), Wanmaishu (CS Bio) and Others......49
Anti-Clotting......50
Table 48: Anti-Clotting Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Enoxaparin, Fondaparinux, Heparin and Xa inhibitors......50
Injectable Drugs......51
Table 49: Market Shares of Leading Injectable Drug Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co. KGaA, Hospira, Inc., Novartis AG, Pfizer, Inc., West-Ward Pharmaceuticals Corporation, and Others......51
Table 50: Market Shares of Leading Generic Injectable Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Fresenius SE & Co., Hikma Pharmaceuticals, Hospira, Inc., Luitpold Pharmaceuticals, Inc. and Others......52
Table 51: Market Shares of Leading Injectable Manufacturers by Value Sales in France (2014) - Percentage Breakdown for Aguettant Limited, Baxter International, Inc., B. Braun Melsungen AG, F. Hoffmann-La Roche Ltd., Lake Forest Park Medical Clinic (LFP), Mylan Laboratories, Inc., Novartis International AG (Sandoz), Laboratoires PANPHARMA S.A., Sanofi S.A., and Others......53
Table 52: Market Shares of Leading Injectable Manufacturers by Value Sales in Germany (2014) - Percentage Breakdown for AstraZeneca Plc, Baxter International, Inc., Fresenius SE & Co., Medac GmbH, Novartis International AG (Sandoz), Sanofi S.A.,Teva Pharmaceutical Industries Ltd. and Others......54
Table 53: Market Shares of Leading Injectable Manufacturers by Value Sales in Italy (2014) - Percentage Breakdown for F. Hoffmann-La Roche Ltd., Hospira, Inc., Johnson & Johnson, KEDRION GROUP S.p.A., Novartis International AG (Sandoz), Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. and Others......55
Table 54: Market Shares of Leading Injectable Manufacturers by Value Sales in Spain (2014) - Percentage Breakdown for F. Hoffmann-La Roche Ltd., Ges Genericos Españoles Laboratorio S.A., Grifols, S.A, Hospira, Inc., Johnson & Johnson, Normon S.A., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Others......56
Table 55: Market Shares of Leading Injectable Manufacturers by Value Sales in the UK (2014) - Percentage Breakdown for Actavis Plc (Watson), AstraZeneca Plc, Baxter International, Inc., Fresenius SE & Co., Hospira, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Others......57
Table 56: Market Shares of Leading Injectable Miotics Manufacturers in the US (2015) - Percentage Breakdown by Value for Alcon Incorporated, and Novartis International AG......58
Orphan Disease Therapeutics......59
Table 57: Market Shares of Leading Orphan Disease Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Pfizer, Inc., Sanofi S.A., and Others......59
Plant Alkaloids......60
Table 58: Plant Alkaloids Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Docetaxel, Irinotecan, Paclitaxel, and Others......60
Docetaxel......61
Table 59: Market Shares of Leading Docetaxel Companies Worldwide (2014) - Percentage Share Breakdown by Value for Jiangsu Hengrui Medicine Co., Ltd., Sanofi S.A., and Others......61
Diclofenac Drug......62
Table 60: Diclofenac Drug Market by Product in China (2015) - Percentage Share Breakdown by Value for Difene (Temmler Werke), Votalin (Novartis), Yingtaiqing (Simcere) and Others......62
Cancer Drugs......63
Table 61: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......63
Table 62: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......64
Table 63: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......65
Table 64: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......66
Table 65: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......67
Breast Cancer Drugs......68
Table 66: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......68
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......69
Table 67: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......69
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......70
Table 68: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......70
Table 69: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......71
Anti-Osteoarthritis Medicine......72
Table 70: Market Shares of Leading Anti-Osteoarthritis Medicine Manufacturers in Korea (2015) - Percentage Breakdown by Value for Humedix Co., Ltd., and Others......72
Critical Care......73
Table 71: Market Shares of Leading Critical Care Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......73
Anti-Clotting......74
Table 72: Market Shares of Leading Anti-Clotting Brands in the US (2015) - Percentage Market Share Breakdown by Value for Arixtra, Enoxaparin, Fonda. - APO, Heparin, Lovenox, and Xarelto......74